CELU Tiesioginiai signalai | Didinkite pelną su Getagraph.com

PIRKIMAS 108041 min ago

@ $0.410

Išleistas: 12 vas. 2024 @ 23:00

Grąža: 636.59%

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 23:00):

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases...

Stats
Šios dienos apimtis	48 969.00
Vidutinė apimtis	96 312.00
Rinkos kapitalizacija	65.78M
EPS	$0 ( 2024-04-02 )
Kita pelno data	( $-0.140 ) 2024-05-27
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.290
ATR14	$0.0260 (0.86%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-13	Fletcher Kyle	Sell	20	Class A Common Stock
2024-04-13	Haines John R	Sell	576	Class A Common Stock
2024-04-13	Beers David C	Sell	360	Class A Common Stock
2024-04-13	Hariri Robert J	Sell	1 154	Class A Common Stock
2024-04-13	Brigido Stephen	Sell	268	Class A Common Stock

INSIDER POWER
57.06
Last 98 transactions
Buy: 89 262 897 \| Sell: 26 354 903

Tūris Koreliacija

Ilgas: -0.01 (neutral)

Trumpas: -0.26 (neutral)

Signal:(49.54) Neutral

Celularity Inc. Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
ASPS	0.945
AUID	0.931
CLFD	0.93
PROG	0.93
OP	0.927
AYLA	0.927
JUPW	0.925
PCSA	0.925
ADP	0.925
DWACU	0.923

10 Labiausiai neigiamai susiję koreliacijos
CBAY	-0.935
TIOA	-0.926
CITE	-0.922
FXCO	-0.917
BWC	-0.915
XPDB	-0.915
BRIV	-0.914
TIOAU	-0.914
ROCL	-0.914
ITAQ	-0.912

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Celularity Inc. Koreliacija - Valiuta/Žaliavos

-0.48
( neutral )

-0.53
( weak negative )

0.00
( neutral )

-0.30
( neutral )

0.19
( neutral )

-0.17
( neutral )

Celularity Inc. Finansinės ataskaitos

Annual	2022
Pajamos:	$17.98M
Bruto pelnas:	$-1.69M (-9.40 %)
EPS:	$1.010

FY	2022
Pajamos:	$17.98M
Bruto pelnas:	$-1.69M (-9.40 %)
EPS:	$1.010

FY	2021
Pajamos:	$21.34M
Bruto pelnas:	$17.69M (82.90 %)
EPS:	$-12.49

FY	2020
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-0.0215

Financial Reports:

No articles found.

Celularity Inc.

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, a placental-derived CAR-T therapy, which is in Phase I clinical trial for the treatment of B-cell malignancies; CYNK-001, placental-derived unmodified natural killer (NK) cell that is in Phase I clinical trial to treat acute myeloid leukemia, as well as in Phase I/IIa clinical trial for the treatment of glioblastoma multiforme and COVID-19; CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I clinical trial to treat HER2+ gastric and gastroesophageal cancers; APPL-001, a placenta-derived mesenchymal-like adherent stromal cell that is in a pre-clinical stage for the treatment of Crohn's disease; and PDA-002, a placenta-derived mesenchymal-like adherent stromal cell, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy. It also sells and licenses products that are used in surgical and wound care markets, such as Biovance and Interfyl; collects stem cells from umbilical cords and placentas; and provides cells storage under the LifebankUSA brand. The company was incorporated in 2016 and is headquartered in Florham Park, New Jersey.